QVAR REDIHALER Rx
Generic Name and Formulations:
Beclomethasone dipropionate HFA 40mcg, 80mcg; per actuation; breath-actuated inhalation aerosol with a dose counter.
Indications for QVAR REDIHALER:
Maintenance treatment of asthma as prophylactic therapy. Limitations of use: not for the relief of acute bronchospasm.
Limitations Of use:
Not for the relief of acute bronchospasm.
Previously not on inhaled corticosteroids: initially 40–80mcg twice daily (approx. 12hrs apart). Previously on inhaled corticosteroids: initially 40–320mcg twice daily. Both: if insufficient response after 2 weeks, increasing the dose may provide additional asthma control; max 320mcg twice daily. Titrate to lowest effective dose after stability achieved. Rinse mouth after use.
<4yrs: not established. 4–11yrs: initially 40mcg twice daily (approx. 12hrs apart). If insufficient response after 2 weeks, increasing the dose may provide additional asthma control; max 80mcg twice daily. Titrate to lowest effective dose after stability achieved. Rinse mouth after use.
Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures.
Do not exceed recommended dose. Risk of local infections (eg, mouth/pharynx candidiasis). Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Immunosuppression: active or quiescent tuberculosis, systemic infections, ocular herpes simplex. If exposed to chickenpox or measles, consider immune globulin or antiviral prophylactic therapies. Monitor for signs/symptoms of adrenal insufficiency when transferring from systemic corticosteroids. May need supplemental systemic corticosteroids during periods of stress or a severe asthma attack. May unmask previously suppressed allergic conditions. Eosinophilic conditions. Reevaluate periodically. Monitor for hypercorticism and HPA axis suppression (if occurs, discontinue gradually), growth in children, or any visual changes. Discontinue if paradoxical bronchospasm occurs; use alternative therapy. Assess bone mineral density if risk factors exist (eg, prolonged immobilization, osteoporosis, or chronic use of drugs that can reduce bone mass [eg, anticonvulsants, oral steroids]). Elderly. Pregnancy: monitor closely. Nursing mothers.
Oral candidiasis, upper respiratory tract infection, nasopharyngitis, allergic rhinitis, oropharyngeal pain, sinusitis; rare: hypersensitivity reactions, psychiatric events and behavioral changes (esp in children).
Inhalation aerosol (w. dose counter)—10.6g (120 inh)
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D